| 54.99 0 (0%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 64.23 | 1-year : | 64.25 |
| Resists | First : | 54.99 | Second : | 55 |
| Pivot price | 54.99 | |||
| Supports | First : | 54.97 | Second : | 45.74 |
| MAs | MA(5) : | 54.99 | MA(20) : | 54.99 |
| MA(100) : | 54.98  |
MA(250) : | 44.47 |
|
| MACD | MACD : | 0  |
Signal : | 0 |
| %K %D | K(14,3) : | 33.3 | D(3) : | 33.3 |
| RSI | RSI(14): 77.7 | |||
| 52-week | High : | 55.18 | Low : | 14.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SRRA ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 139 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 55.14 - 55.41 | 55.41 - 55.63 |
| Low: | 54.21 - 54.59 | 54.59 - 54.9 |
| Close: | 54.47 - 55.03 | 55.03 - 55.49 |
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Fri, 17 Jun 2022
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration - Business Wire
Wed, 13 Apr 2022
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn - Business Wire
Wed, 13 Apr 2022
Why Is Sierra Oncology (SRRA) Stock Up Today? - Yahoo Finance
Thu, 10 Mar 2022
Sierra Oncology Reports 2021 Year End Results - Business Wire
Mon, 31 Jan 2022
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities - Business Wire
Wed, 26 Jan 2022
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 24 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 76.9 (%) |
| Shares Short | 572 (K) |
| Shares Short P.Month | 890 (K) |
| EPS | -6.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.9 % |
| Return on Equity (ttm) | -56.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.46 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -88 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -8.35 |
| PEG Ratio | -0.2 |
| Price to Book value | 5 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2020-01-22 |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|